Carvedilol in children with cardiomyopathy: 3-Year experience at a single institution

Journal of Heart and Lung Transplantation

Volumn 23, Issue 7, 2004, Pages 832-838

  Rusconi, Paolo ^a   Gómez Marín, Orlando ^a   Rossique González, Marie ^b   Redha, Esmail ^a   Marín, Jennifer R ^a   Lon Young, Ming ^a   Wolff, Grace S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN ANTAGONIST; CARVEDILOL; DIGOXIN; DIURETIC AGENT;

ADOLESCENT; ASTHMA; BRADYCARDIA; CARDIOMYOPATHY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEADACHE; HEART BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; HYPOTENSION; MALE; MEDICAL RECORD; MORTALITY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; VOMITING;

EID: 3242694962     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2003.07.025     Document Type: Article

References (30)

1. Grenier M.A., Osganian S.K., Cox G.F., et al. Design and implementation of the North American Pediatric Cardiomyopathy Registry. Am Heart J. 139:(suppl):2000;S86-95
2. Lewis A.B., Chabot M. Outcome of infants and children with dilated cardiomyopathy. Am J Cardiol. 68:1991;365-369
3. Lewis A.B. Prognostic value of echocardiography in children with dilated cardiomyopathy. Am Heart J. 128:1994;133-136
4. Arola A., Tuominen J., Ruuskanen O., Jokinen E. Idiopathic dilated cardiomyopathy in children prognostic indicators and outcome. Pediatrics. 101:1998;369-376
5. Akagi T., Benson L.N., Lightwood N.E., Chin K., Wilson G., Freedom R.M. Natural history of dilated cardiomyopathy in children. Am Heart J. 121:1991;1502-1506
6. Lewis A.B. Late recovery of ventricular function in children with idiopathic dilated cardiomyopathy. Am Heart J. 138:1999;334-338
7. Webber S.A. 15 years of pediatric heart transplantation at the University of Pittsburgh lessons learned and future prospects. Pediatr Transplant. 1:1997;8-21
8. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 334:1996;1349-1355
9. Doughty R., Whalley G., Gamble G., et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol. 29:1997;1060-1066
10. Colucci W.S., Packer M., Bristow M.R., et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 94:1996;2800-2806
11. Packer M., Colucci W.S., Sackner-Bernstein J.D., et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective randomized evaluation of carvedilol on symptoms and exercise. Circulation. 94:1996;2793-2799
12. Cice G., Tagliamonte E., Ferrara L., Iacono A. Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy double-blind, randomized, placebo-controlled study. Eur Heart J. 21:2000;1259-1264
13. The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Lancet. 353:1999;2001-2007
14. Hialmarson A., Goldstein S., Fagerberg B., et al. Effect of controlled-release metoprolol on total mortality, hospitalization and well-being in patients with heart failure the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure MERIT-HF Study Group. JAMA. 283:2000;1295-1302
15. CIBIS investigators and committees. A randomized trial of beta-blockers in heart failure. The Cardiac Insufficiency Bisoprolol Study. Circulation. 90:1994;1765-1773
16. CIBIS II investigators and committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II). II. A randomized trial. Lancet. 353:1999;9-13
17. Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet. 26:1994;335-346
18. Ruffolo R.R. Jr, Gellai M., Heible J.P., Willette R.N., Nicholas A.J. The pharmacology of carvedilol. Eur J Clin Pharmacol. 38:(suppl):1990;S82-88
19. Yoshikawa T., Port J.D., Asano K., et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J. 17:(supplB):1996;8-16
20. Yue T.-L., Cheng H.-Y., Lysko P.G., et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 263:1992;92-98
21. Feuerstein G.Z., Ruffolo R.R. Jr. Carvedilol a novel vasodilating beta-blocker with the potential for cardiovascular protection. Eur Heart J. 17:(supplB):1996;24-29
22. Wahr D.W., Wang Y.S., Schiller N.B. Left ventricular volumes determined by two-dimensional echocardiography in a normal adult population. J Am Coll Cardiol. 1:1983;863-868
23. Bruns L.A., Kichuk Chrisant M., Lamour J., et al. Carvedilol as therapy in pediatric heart failure an initial multicenter experience. J Pediatr. 138:2001;505-511
24. Matitiau A., Perez-Atayde A., Sanders S.P., Sluysmans T., Parness I.A., Spevak P.J., Colan S.D. Infantile dilated cardiomyopathy. Relation of outcome to left ventricular mechanics, hemodynamics, and histology at the time of presentation. Circulation. 90:1994;1310-1318
25. Packer M. Pathophysiology of chronic heart failure. Lancet. 340:1992;88-92
26. Bristow M. β-Adrenergic receptor blocked in congestive heart failure. Circulation. 101:2000;558-569
27. Simons M., Downing S.E. Coronary vasoconstriction and catecholamine cardiomyopathy. Am Heart J. 109:1985;297-304
28. Packer M. Current role of beta-adrenergic blockers in the management of chronic heart failure. Am J Med. 110:(suppl):2001;81S-94S
29. Feuerstein G.Z., Bril A., Ruffolo R.R. Jr. Protective effects of carvedilol in the myocardium. Am J Cardiol. 80:1997;41L-45
30. Hansson L, Himmelmann A. Carvedilol in the treatment of hypertension - a review of the clinical database. Scand Cardiovasc J 1998 (suppl)47:67-80